HIV Protease Inhibitors and the Hepatic Metabolome
Oliver P. Flint1, Caroline Elosua1, Rex A. Parker1, Mustafa Noor1, Carol Hamilton21Pharmaceutical Research Institute, Bristol-Myers Squibb Company, Princeton, NJ, USA
2Metabolon, Inc., Research Triangle Park, NC USASummary: In order to further understand the implications of differential effects of HIV protease inhibitors on the overall cellular metabolic state, a metabolomic analysis was completed of HepG2 hepatomas exposed to five different protease inhibitors in vitro.
Request Poster
|
Identification of Metabolic Biomarkers for Amyotrophic Lateral Sclerosis
K.A. Lawton1, L.A. Paige1, M. Mitchell1, R. Kaddurah-Daouk3, R. H. Brown2, M. Milburn1, M.E. Cudkowicz21Metabolon, Inc., Research Triangle Park, NC USA
2Massachusetts General Hospital, Alzheimer’s Disease Research Unit, Charlestown, MA USA 02129
3Duke University Medical Center, Durham, NC 27710 Summary: To discover metabolic biomarkers that will provide diagnostic and therapeutic benefits for Amyotrophic Lateral Sclerosis (ALS), metabolomic analysis was carried out on over 350 plasma samples collected from ALS patients and heavily controlled subjects. Compounds that show statistically significant changes in ALS compared to the healthy controls were discovered; these compounds are disease biomarker candidates.
Request Poster
|
VPHIL: Software for Performing Compound Identification QC on Large Metabolomic Datasets
Corey DeHaven and Tom BarrettMetabolon, Inc. Research Triangle Park, NC USA Summary: VPHIL provides analysts many options for quickly performing rapid quality control of metabolomic data. The ability to analyze and perform QC on large-scale, multi-sample metabolomics data on an industrial scale is an important step in the evolution of the technology as a whole.
Request Poster
|
|
Previous123456Next
|